Table 2.
Key randomized phase III trial with targeted agents in previously untreated gastric cancer.
| Trial name | Selected biomarker | Treatment | Number of patients | Primary endpoint | Hazard ratio (95% confidence interval) | p value | Median OS (months) |
|---|---|---|---|---|---|---|---|
| ToGA[Bang et al. 2010] | HER2 expression/amplification | CF/CXCF/CX +trastuzumab | 290294 | OS | 0.74 (0.60–0.91) | 0.004 | 13.811.1 |
| LOGiC[Hecht et al. 2013] | HER2 expression/amplification | CapeOXCapeOx+lapatinib | 273272 | OS | 0.91 (0.73–1.12) | 0.35 | 10.512.2 |
| REAL-3 | all comers | EOX | 275 | OS | 1.37 (1.07–1.76) | 0.013 | 11.3 |
| [Waddell et al. 2013] | EOX+panitumumab | 278 | 8.8 | ||||
| EXPAND | all comers | CX | 449 | PFS | 1.09 (0.92–1.29) | 0.32 | 10.7 |
| [Lordick et al. 2013] | CX+cetuximab | 445 | 9.4 | ||||
| RILOMET[Cunningham et al. 2015] | MET positive by IHC HER2 negative | ECXECX+rilotumumab | 305304 | OS | 1.37 (1.06–1.78) | 0.016 | 11.5 9.6 |
| AVAGAST | all comers | CX | 387 | OS | 0.87 (0.73–1.03) | 0.1 | 10.1 |
| [Ohtsu et al. 2011] | CX+bevacizumab | 387 | 12.1 | ||||
| AVATAR | all comers | CX | 102 | OS | 1.11 (0.79–1.56) | 0.5567 | 11.4 |
| [Shen et al. 2015] | CX+bevacizumab | 100 | 10.5 |
CapeOX, capecitabine, oxaliplatin; CF, cisplatin, fluorouracil; CX, cisplatin, capecitabine; ECX, epirubicin, cisplatin and capecitabine; EOX, epirubicine, oxaliplatin, capecitabine; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; OS, overall surivial; PFS, progression-free survival.